Compare PulteGroup, Inc. (PHM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PulteGroup, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? PulteGroup, Inc. trades at $118.95 (market cap $22.87B), while State Street SPDR S&P Biotech ETF trades at $159.89. The key difference: PulteGroup, Inc. pays a 0.87% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, PulteGroup, Inc. nearer its low. Which is the better fit depends on your goals.
| PHM | XBI | |
|---|---|---|
Market Cap | $22.87B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $142.56 | $169.55 |
52-Week Low | $110.11 | $93.43 |
Enterprise Value | $23.28B | — |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.
The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
